Navigation Links
Anti-psychotic medications offer new hope in the battle against glioblastoma
Date:3/7/2014

Researchers at the University of California, San Diego School of Medicine have discovered that FDA-approved anti-psychotic drugs possess tumor-killing activity against the most aggressive form of primary brain cancer, glioblastoma. The finding was published in this week's online edition of Oncotarget.

The team of scientists, led by principal investigator, Clark C. Chen, MD, PhD, vice-chairman, UC San Diego, School of Medicine, division of neurosurgery, used a technology platform called shRNA to test how each gene in the human genome contributed to glioblastoma growth. The discovery that led to the shRNA technology won the Nobel Prize in Physiology/Medicine in 2006.

"ShRNAs are invaluable tools in the study of what genes do. They function like molecular erasers," said Chen. "We can design these 'erasers' against every gene in the human genome. These shRNAs can then be packaged into viruses and introduced into cancer cells. If a gene is required for glioblastoma growth and the shRNA erases the function of that gene, then the cancer cell will either stop growing or die."

Chen said that one surprising finding is that many genes required for glioblastoma growth are also required for dopamine receptor function. Dopamine is a small molecule that is released by nerve cells and binds to the dopamine receptor in surrounding nerve cells, enabling cell communication.

Abnormal dopamine regulation is associated with Parkinson's disease, schizophrenia, and Attention Deficit Hyperactivity Disorder. Because of the importance of dopamine in these diseases, drugs have been developed to neutralize the effect of dopamine, called dopamine antagonists.

Following clues unveiled by their shRNA study, Chen and his team tested the effects of dopamine antagonists against glioblastoma and found that these drugs exert significant anti-tumor effects both in cultured cells and mouse models. These effects are synergistic when combined with other anti-glioblastoma drugs in terms of halting tumor growth.

"The anti-glioblastoma effects of these drugs are completely unexpected and were only uncovered because we carried out an unbiased genetic screen," said Chen.

"On the clinical front, the finding is important for two reasons," said Bob Carter, MD, PhD, chairman of UC San Diego, School of Medicine, division of neurosurgery. "First, these drugs are already FDA-cleared for human use in the treatment of other diseases, so it is possible these drugs may be re-purposed for glioblastoma treatment, thereby bypassing years of pre-clinical testing. Second, these drugs have been shown to cross the blood-brain barrier, a barrier that prevents more than 90 percent of drugs from entry into the brain."

Chen is now working with the UC San Diego Moores Cancer Center Neuro-Oncology team to translate his findings into a clinical trial.


'/>"/>
Contact: Jackie Carr
jcarr@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert  

Related medicine news :

1. New Risperdal Lawsuit Filed in Pennsylvania Litigation; Alleges Male Breast Growth Injuries Caused by Anti-Psychotic Medication, Bernstein Liebhard LLP Reports
2. Blood pressure medications given right after stroke not beneficial, study finds
3. MIT robot may accelerate trials for stroke medications
4. Fresno California's Hear for Life Hearing Aid Centers Publishes Warnings about Medications that Lead to Hearing Loss
5. Audiologists at American Hearing & Balance in Marina del Rey CA Educate Consumers About Everyday Medications That Cause Hearing Loss
6. Bernstein Liebhard LLP Launches New GranuFlo Lawsuit Website for Individuals Allegedly Injured by Recalled Dialysis Medications
7. Effect of reducing blood pressure with medications immediately following ischemic stroke
8. Watchful Waiting Can Do the Job of BPH Medications For Some Men, From the November 2013 Harvard Men's Health Watch
9. Racial difference in blood clotting warrants a closer look at heart attack medications
10. Mothers immunosuppressive medications not likely to put fetus at risk
11. Pain Management Therapeutics Market to 2019 - Impact of Patent Expiries Offset by Demand for Neuropathic and Rheumatoid Pain Medications and Strong Pipeline
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Anti-psychotic medications offer new hope in the battle against glioblastoma
(Date:2/18/2017)... (PRWEB) , ... February 17, 2017 , ... ... , drvallecillos.com , Beverly Hills plastic surgeon Dr. Glenn Vallecillos ... cells. , Dr. Vallecillos says, "Traditionally, plastic surgery has been centered around that ...
(Date:2/17/2017)... , ... February 17, 2017 , ... Smiles by Seese ... Center in Davidson, NC. Dr. Brian Seese leads the practice as a skilled and ... under one roof. Smiles by Seese serves patients of all ages with excellence in ...
(Date:2/17/2017)... ... February 17, 2017 , ... For the ... management solution to the exhibit floor for the 2017 HIMSS Conference & ... From Feb. 19–23, 2017, more than 40,000 healthcare industry professionals are expected at ...
(Date:2/17/2017)... ... 2017 , ... Qualis Health, one of the nation's leading ... DecisionHealth Platinum Awards in recognition of its innovative healthcare management programs that are ... award categories, highlighting four of the organization’s current programs:, , ...
(Date:2/17/2017)... ... February 17, 2017 , ... Pharmica Consulting attended CHI's ... facets of clinical trial planning and management. Pharmica discussed the importance of effective ... addition, attendees stopping by Pharmica’s booth were able to demo its cloud-based ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... , Feb. 17, 2017  Noble Capital Markets ... ESSA Pharma Inc. (Nasdaq: EPIX ). The ... Kumar Raja , PhD. ESSA Pharmaceuticals ... castration resistant prostate cancer (CRPC). Its lead compound EPI-506, ... the amino-terminal domain of the androgen receptor, thereby has ...
(Date:2/16/2017)... 16, 2017 Research and Markets has ... Medical Device Technologies" report to their offering. ... Traditional medical ... general instruments, non-drug coated implantables, large endoscopes, needle based drug ... over the last two to three decades for the treatment ...
(Date:2/16/2017)... DaVita Inc. (NYSE: DVA ) today announced results ... Net income attributable to DaVita Inc. for the ... or $0.80 per share and $880 million, or $4.29 per ... DaVita Inc. for the quarter and year ended December 31, ... or $0.98 per share, and $789 million, or $3.85 per ...
Breaking Medicine Technology: